Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | $306M | $412M | $812M |
| Revenue growth | — | 34.7% | 97.0% |
| Operating income | -$320M | -$257M | $45.1M |
| Operating margin | -104.4% | -62.4% | 5.6% |
| Net income | -$341M | -$282M | -$68.1M |
| Net margin | -111.5% | -68.4% | -8.4% |
| EPS (diluted) | -$13.24 | -$10.66 | -$3.22 |
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Operating cash flow | -$276M | -$245M | $83.2M |
| Capital expenditures | $22.3M | $8.44M | $16.3M |
| Free cash flow | -$298M | -$254M | $66.9M |
| Share buybacks | $0.00 | $0.00 | $113K |
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Cash & equivalents | — | $64.0M | $796M |
| Total assets | — | $344M | $1.13B |
| Total liabilities | — | $621M | $548M |
| Long-term debt | — | $319M | $379M |
| Shareholders' equity | -$2.14B | -$2.50B | $577M |
| Retained earnings | — | -$2.47B | -$2.55B |
| Shares (wtd avg diluted) | 34.9M | 35.5M | 167M |
Every figure is extracted from Caris Life Sciences, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.